Assessing Functionality and Benefits of Comprehensive Dose Volume Prescriptions: An International, Multi-Institutional, Treatment Planning Study in Spine Stereotactic Body Radiation Therapy

Respiratory motion tracking of spine stereotactic radiotherapy in prone position

PURPOSE

The CyberKnife system is a specialized device for non-coplanar irradiation; however, it possesses the geometric restriction that the beam cannot be irradiated from under the treatment couch. Prone positioning is expected to reduce the dose to normal lung tissue in spinal stereotactic body radiotherapy (SBRT) owing to the efficiency of beam arrangement; however, respiratory motion occurs. Therefore, the Xsight spine prone tracking (XSPT) system is used to reduce the effects of respiratory motion. The purpose of this study was to evaluate the motion-tracking error of the spine in the prone position.

MATERIALS AND METHODS

Data from all 25 patients who underwent spinal SBRT at our institution between April 2020 and February 2022 using CyberKnife (VSI, version 11.1.0) with the XSPT tracking system were retrospectively analyzed using log files. The tumor motion, correlation, and prediction errors for each patient were examined. Furthermore, to assess the potential relationships between the parameters, the relationships between the tumor-motion amplitudes and correlation or prediction errors were investigated using linear regression.

RESULTS

The tumor-motion amplitudes in each direction were as follows: superior-inferior (SI), 0.51 ± 0.39 mm; left-right (LR), 0.37 ± 0.29 mm; and anterior-posterior (AP), 3.43 ± 1.63 mm. The overall mean correlation and prediction errors were 0.66 ± 0.48 mm and 0.06 ± 0.07 mm, respectively. The prediction errors were strongly correlated with the tumor-motion amplitudes, whereas the correlation errors were not.

CONCLUSIONS

This study demonstrated that the correlation error of spinal SBRT in the prone position is sufficiently small to be independent of the tumor-motion amplitude. Furthermore, the prediction error is small, contributing only slightly to the tracking error. These findings will improve the understanding of how to compensate for respiratory-motion uncertainty in the prone position.

Stereotactic Body Radiation Therapy for Spinal Metastases: Tumor Control Probability Analyses and Recommended Reporting Standards

PURPOSE

We sought to investigate the tumor control probability (TCP) of spinal metastases treated with stereotactic body radiation therapy (SBRT) in 1 to 5 fractions.

METHODS AND MATERIALS

PubMed-indexed articles from 1995 to 2018 were eligible for data extraction if they contained SBRT dosimetric details correlated with actuarial 2-year local tumor control rates. Logistic dose-response models of collected data were compared in terms of physical dose and 3-fraction equivalent dose.

RESULTS

Data were extracted from 24 articles with 2619 spinal metastases. Physical dose TCP modeling of 2-year local tumor control from the single-fraction data were compared with data from 2 to 5 fractions, resulting in an estimated α/β = 6 Gy, and this was used to pool data. Acknowledging the uncertainty intrinsic to the data extraction and modeling process, the 90% TCP corresponded to 20 Gy in 1 fraction, 28 Gy in 2 fractions, 33 Gy in 3 fractions, and (with extrapolation) 40 Gy in 5 fractions. The estimated TCP for common fractionation schemes was 82% at 18 Gy, 90% for 20 Gy, and 96% for 24 Gy in a single fraction, 82% for 24 Gy in 2 fractions, and 78% for 27 Gy in 3 fractions.

CONCLUSIONS

Spinal SBRT with the most common fractionation schemes yields 2-year estimates of local control of 82% to 96%. Given the heterogeneity in the tumor control estimates extracted from the literature, with variability in reporting of dosimetry data and the definition of and statistical methods of reporting tumor control, care should be taken interpreting the resultant model-based estimates. Depending on the clinical intent, the improved TCP with higher dose regimens should be weighed against the potential risks for greater toxicity. We encourage future reports to provide full dosimetric data correlated with tumor local control to allow future efforts of modeling pooled data.

Precision Stereotactic Radiotherapy for Spinal Tumors: Mechanism, Efficacy, and Issues

Stereotactic ablative radiotherapy (SABR/SBRT) is a revolutionary technique for tumor therapy. Its advantages are especially beneficial for the treatment spinal tumors. It has a wide range of indications in radiotherapy alone and in preoperative and postoperative treatments for spinal tumor. The mechanism of stereotactic radiotherapy for spinal tumors is special, and completely different from traditional radiotherapy. Compared with traditional radiotherapy, SBRT creates more DNA double-strand breaks, leads to less DNA damage repair, and also has anti-vascular effects, in situ vaccine effects and abscopal effect. In the present study, the literature regarding SABR for the treatment of spinal tumors is summarized, and we reviewed characteristics of SABR and spinal tumors, as well as the clinical efficacy and toxicity of SABR in treating spinal tumors. In addition, we proposed several issues around the SABR treatment of spinal tumor, the standard of treatment dose, and the post-treatment follow-up. We also made predictions with respect to future management of spinal tumors, SABR development, multi-modality integration between SABR and other treatments, and other future development trends, thereby providing future research directions as a contribution to the field.

A prospective multicentre feasibility study of stereotactic body radiotherapy in Japanese patients with spinal metastases

OBJECTIVE

Stereotactic body radiotherapy has emerged as an attractive alternative to conventional radiotherapy for spinal metastases. However, it has limitations, including the need for advanced techniques and specific adverse effects. The present trial aimed to validate the feasibility and safety of stereotactic body radiotherapy in Japanese patients with spinal metastases.

METHODS

Patients with one or two spinal metastases received stereotactic body radiotherapy of 24 Gy in two fractions. The primary endpoint was the proportion of severe adverse effects (≥ grade 3) in patients within 6 months after spine stereotactic body radiotherapy. Adverse effects were evaluated according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4. The treatment protocol was considered feasible and tolerable if the proportion of severe adverse effects was 10% or less.

RESULTS

Overall, 20 spinal segments in 20 patients who registered between March 2014 and October 2015 were included. Minor and major deviations were observed in the planning of 2 and 0 cases, respectively. The treatment completion rate was 100%. The median follow-up after registration was 24.5 (range: 1-61) months. Although four patients experienced acute grade 2 adverse effects, no grade 3 or higher adverse effects were observed within 6 months after spine stereotactic body radiotherapy. Vertebral compression fractures were observed in two patients (14 and 16 months after stereotactic body radiotherapy). The local control and pain response rates at 6 months were 100 and 83%, respectively.

CONCLUSION

This study demonstrated the feasibility and safety of spine stereotactic body radiotherapy in Japanese patients with spinal metastases.

Dosimetric comparison of two treatment planning systems for spine SBRT

Two commonly used treatment planning systems (TPS) are compared for the planning of spine stereotactic body radiotherapy (SBRT). The main purpose is to highlight relative advantages and disadvantages of each system and propose a methodologic approach for comparisons. Twenty clinical plans were inversely planned with step-and-shoot intensity-modulated radiotherapy (IMRT) each using 9 to 11 beams, referred to as IMRT_P. The prescription dose was 24 Gy in 2 fractions, and the plans were generated following our institutional protocol using the Pinnacle³ v9.2. Each case was replanned using a 2-arc volumetric modulated arc therapy (VMAT) approach, referred as VMAT_P. CT and structure sets were DICOM exported to Monaco v5.10 and planned in 2 different ways: IMRT (IMRT_M) and VMAT (VMAT_M) using the same prescription dose. Dose volume histograms (DVH) and other dose statistics of planning target volumes (PTV) and organ-at-risk (OAR) were analyzed and compared between plans. The gradient index (GI = ratio of 50% isodose volume to prescribed isodose volume) was used to measure dose fall-off outside of the PTV. Another metric - Gradient Index Inner (GI_inner = the rate (in Gy/mm) - at which the dose changes from the level of the spinal cord/thecal sac toward the prescription dose) was developed and compared. All plans were considered clinically acceptable by institutional guidelines and achieved all of the OAR dose constraints. VMAT_M and IMRT_M showed comparable dose statistics for the PTV when compared to VMAT_P and IMRT_P, respectively. For IMRT plans, the median GI_inner was 1.88 Gy/mm vs 1.52 Gy/mm for IMRT_M and IMRT_P respectively (p< 0.001). All other IMRT metrics were statistically similar except for the PTV maximum dose (D_max), which was higher for IMRT_M than IMRT_P (median 30.7 Gy vs 29.0 Gy, p< 0.001). For VMAT plans, only PTV D_min showed a statistical different between VMAT_M and VMAT_P of median 12.7 Gy vs 9.7 Gy (p< 0.001). In terms of beam sequencing parameters, the number of monitor units was statistically higher for VMAT_P compared to VMAT_M (median = 6764 vs 5376) whereas the number of segments for IMRT_M was statistically greater than IMRT_P (median = 155 vs 73). We were able to generate clinically acceptable plans for different types of spine SBRT using 2 different TPS. We used an evaluation strategy involving coverage, conformity, and dose gradient that can compared between TPS.

Simulating imaging-based tomographic systems using optical design software for resolving 3D structures of translucent media

Imaging-based tomography is emerging as the technique of choice for resolving 3D structures of translucent media, in particular for applications in external beam radiation therapy and combustion diagnostics. However, designing experimental prototypes is time-consuming and costly, and is carried out without the certainty of the imaging optics being optimal. In this paper, we present an optical-design-software-based method that enables end-to-end simulation imaging-based tomography systems. The method, developed using the real ray tracing features of Zemax OpticStudio, was validated in the context of 3D scintillation dosimetry, where multiple imaging systems are used to image the 3D light pattern emitted within an irradiated cubic plastic scintillator volume. The flexibility of the workflow enabled the assessment and comparison of the tomographic performance of standard and focused plenoptic cameras for the reconstruction of a clinical radiation dose distribution. The versatility of the proposed method offers the potential to ease the developmental and optimization process of imaging systems used in volumetric emission computed tomography applications.

Feasibility of spine stereotactic body radiotherapy for patients with large tumors in multiple vertebrae undergoing re-irradiation: Dosimetric challenge using 3 different beam delivery techniques

The objective of the present study was to report whether the adequate spine stereotactic body radiotherapy (SBRT) plans were generated with feasible treatment duration for patients with large vertebral metastases undergoing re-irradiation. For 5 cases, the re-irradiation plans using static-field intensity-modulated radiation therapy (SIMRT), volumetric-modulated arc therapy (VMAT), and CyberKnife with a total prescribed dose (PD) of 24 Gy applied in 2 fractions were generated. A minimum dose to 95% of the evaluated planning target volume (PTV_evl) that was >70% of PD (D₉₅ > 70% PD) was defined as minimum criterion. For the dose tolerance of the spinal cord or thecal sac, which could affect the risk of radiation myelopathy, a volume-dose constraint of 12.2 Gy was set for the planning organ-at-risk volume of the spinal cord (PRV_cord) or thecal sac and limited to 0.035 cc (D_{0.035 cc}< 12.2 Gy) on the re-irradiation plans. For assessing the impact of the stricter dose constraint of PRV_cord on the plan quality, we generated plans with a PRV_cord dose constraint of D_{0.035 cc} < 17.0 Gy, which was employed for patients with no previous history of radiation therapy (RT). Dose-volume histogram (DVH) analysis was performed for the PTV_evl and spinal cord. Median PTV_evl of all cases was 242.3 cc (range; 159.2 to 722.4 cc). Two out of 5 cases had a PTV_evl >500 cc. The constraint of the PRV_cord D_0.035cc was met in all re-irradiation plans; however, a comparison between the re-irradiation plan for patients with large vertebral metastases and the plan for cases with no RT history showed that the decrease of the target dose coverage was correlated with the stricter dose constraint of the PRV_cord. For SIMRT and VMAT, the re-irradiation plans met the goal of the PTV_evl D₉₅. On the other hand, CyberKnife plans could not achieve the constraints of the PTV_evl D₉₅. This discrepancy is due to the constraint of treatment duration, which is defined as the comfortable duration for patients with large spinal metastases. Regardless of the delivery method used, treatment plan quality is impacted to a greater extent by the dose tolerance of the spinal cord than by the size of the tumor.